These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
750 related articles for article (PubMed ID: 20586616)
1. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Hammond ME; Hayes DF; Dowsett M; Allred DC; Hagerty KL; Badve S; Fitzgibbons PL; Francis G; Goldstein NS; Hayes M; Hicks DG; Lester S; Love R; Mangu PB; McShane L; Miller K; Osborne CK; Paik S; Perlmutter J; Rhodes A; Sasano H; Schwartz JN; Sweep FC; Taube S; Torlakovic EE; Valenstein P; Viale G; Visscher D; Wheeler T; Williams RB; Wittliff JL; Wolff AC; ; Arch Pathol Lab Med; 2010 Jul; 134(7):e48-72. PubMed ID: 20586616 [TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Hammond ME; Hayes DF; Dowsett M; Allred DC; Hagerty KL; Badve S; Fitzgibbons PL; Francis G; Goldstein NS; Hayes M; Hicks DG; Lester S; Love R; Mangu PB; McShane L; Miller K; Osborne CK; Paik S; Perlmutter J; Rhodes A; Sasano H; Schwartz JN; Sweep FC; Taube S; Torlakovic EE; Valenstein P; Viale G; Visscher D; Wheeler T; Williams RB; Wittliff JL; Wolff AC J Clin Oncol; 2010 Jun; 28(16):2784-95. PubMed ID: 20404251 [TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Hammond ME; Hayes DF; Dowsett M; Allred DC; Hagerty KL; Badve S; Fitzgibbons PL; Francis G; Goldstein NS; Hayes M; Hicks DG; Lester S; Love R; Mangu PB; McShane L; Miller K; Osborne CK; Paik S; Perlmutter J; Rhodes A; Sasano H; Schwartz JN; Sweep FC; Taube S; Torlakovic EE; Valenstein P; Viale G; Visscher D; Wheeler T; Williams RB; Wittliff JL; Wolff AC Arch Pathol Lab Med; 2010 Jun; 134(6):907-22. PubMed ID: 20524868 [TBL] [Abstract][Full Text] [Related]
4. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Allison KH; Hammond MEH; Dowsett M; McKernin SE; Carey LA; Fitzgibbons PL; Hayes DF; Lakhani SR; Chavez-MacGregor M; Perlmutter J; Perou CM; Regan MM; Rimm DL; Symmans WF; Torlakovic EE; Varella L; Viale G; Weisberg TF; McShane LM; Wolff AC J Clin Oncol; 2020 Apr; 38(12):1346-1366. PubMed ID: 31928404 [TBL] [Abstract][Full Text] [Related]
5. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Allison KH; Hammond MEH; Dowsett M; McKernin SE; Carey LA; Fitzgibbons PL; Hayes DF; Lakhani SR; Chavez-MacGregor M; Perlmutter J; Perou CM; Regan MM; Rimm DL; Symmans WF; Torlakovic EE; Varella L; Viale G; Weisberg TF; McShane LM; Wolff AC Arch Pathol Lab Med; 2020 May; 144(5):545-563. PubMed ID: 31928354 [TBL] [Abstract][Full Text] [Related]
6. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. Allred DC; Carlson RW; Berry DA; Burstein HJ; Edge SB; Goldstein LJ; Gown A; Hammond ME; Iglehart JD; Moench S; Pierce LJ; Ravdin P; Schnitt SJ; Wolff AC J Natl Compr Canc Netw; 2009 Sep; 7 Suppl 6():S1-S21; quiz S22-3. PubMed ID: 19755043 [TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF; Arch Pathol Lab Med; 2007; 131(1):18-43. PubMed ID: 19548375 [TBL] [Abstract][Full Text] [Related]
8. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF; ; J Clin Oncol; 2007 Jan; 25(1):118-45. PubMed ID: 17159189 [TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487 [TBL] [Abstract][Full Text] [Related]
10. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B; J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359 [TBL] [Abstract][Full Text] [Related]
11. Estrogen and progesterone receptor assay in paraffin-embedded breast cancer--reproducibility of assessment. Chebil G; Bendahl PO; Fernö M; ; Acta Oncol; 2003; 42(1):43-7. PubMed ID: 12665330 [TBL] [Abstract][Full Text] [Related]
12. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. Henry NL; Somerfield MR; Abramson VG; Allison KH; Anders CK; Chingos DT; Hurria A; Openshaw TH; Krop IE J Clin Oncol; 2016 Jul; 34(19):2303-11. PubMed ID: 27001586 [TBL] [Abstract][Full Text] [Related]
13. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence. Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L Tumori; 2015; 101(4):398-403. PubMed ID: 26045108 [TBL] [Abstract][Full Text] [Related]
14. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. Hammond ME; Hayes DF; Wolff AC J Clin Oncol; 2011 May; 29(15):e458. PubMed ID: 21502545 [No Abstract] [Full Text] [Related]
15. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Harris LN; Ismaila N; McShane LM; Andre F; Collyar DE; Gonzalez-Angulo AM; Hammond EH; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Bast RC; Hayes DF; J Clin Oncol; 2016 Apr; 34(10):1134-50. PubMed ID: 26858339 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Estrogen and Progesterone Receptor Antibody Reagents Using Proficiency Testing Data. Troxell ML; Long T; Hornick JL; Ambaye AB; Jensen KC Arch Pathol Lab Med; 2017 Oct; 141(10):1402-1412. PubMed ID: 28714765 [TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact? Kunc M; Biernat W; Senkus-Konefka E Cancer Treat Rev; 2018 Jun; 67():78-87. PubMed ID: 29772460 [TBL] [Abstract][Full Text] [Related]
18. Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation. Jorns JM Arch Pathol Lab Med; 2019 Dec; 143(12):1444-1449. PubMed ID: 31373514 [TBL] [Abstract][Full Text] [Related]
19. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study. Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860 [TBL] [Abstract][Full Text] [Related]
20. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]